A Randomized Clinical Trial of a Standardized Pumpkin-Seed-Derived Peptide Extract: Body Composition Outcomes and Exploratory Analysis by Baseline Adiposity in Overweight Adults.

title: "Pumpkin-Seed Peptide Extract and Body Composition: What a 12-Week Trial Found"

description: "A randomized, placebo-controlled trial of a standardized pumpkin-seed-derived peptide extract found no overall effect on body composition, with exploratory subgroup signals that require prospective confirmation."

date: 2025-01-01

category: research-update

evidence_tier: "C"

TL;DR: A 12-week randomized, placebo-controlled trial of a standardized pumpkin-seed peptide extract found no statistically significant difference in body weight, BMI, or adiposity across all 48 evaluable participants. A post hoc subgroup of higher-fat participants showed nominal between-group differences, but these were exploratory, unadjusted for multiple comparisons, and should be treated as a hypothesis for future trials. Evidence tier: C (single small RCT, exploratory subgroup findings).

What the study found

The trial, published in *International Journal of Molecular Sciences*, enrolled 50 overweight adults and randomized them to receive either 600 mg/day of a standardized pumpkin-seed-derived preparation (IRK-19, a registered product name) or placebo for 12 weeks. Participants and investigators were blinded to allocation. Of the 50 enrolled, 48 had evaluable DXA body composition data at Week 12.

The study team characterized the preparation before testing it. It contained 66.2% crude protein, with components of apparent molecular weight at or below 6.29 kDa accounting for 23.6% of the total SEC-UV chromatographic area. Six selected peptide markers, measured by HPLC, together made up 2.79% of the product by weight. This characterization matters because "pumpkin seed extract" is not a single defined compound, and results from one standardized preparation cannot be assumed to apply to others.

In the full study population, between-group comparisons of body weight, BMI, and adiposity-related outcomes did not reach statistical significance. This is the primary result, and it is a null result. The trial did not show that the extract changed body weight or body composition across overweight adults as a group.

The authors also ran a post hoc exploratory analysis in a subgroup defined by baseline total fat mass at or above 28.4 kg, the study-specific 75th percentile (n = 13). In this subgroup, adjusted between-group differences (extract minus placebo) at Week 12 were:

Body weight: -2.30 kg (95% CI, -4.08 to -0.51; p = 0.018)

BMI: -0.75 kg/m² (95% CI, -1.48 to -0.02; p = 0.045)

Total fat mass: -1.60 kg (95% CI, -3.23 to 0.04; p = 0.055)

These numbers look more favorable than the overall result, and they should be read with care. The subgroup was defined after the data were seen, contained only 13 participants, and the authors did not adjust for multiple comparisons. The treatment-by-baseline-fat-mass interaction tests did not reach significance for body weight, BMI, or fat mass (p = 0.065, 0.106, and 0.057). In plain terms, the data do not establish that baseline fat mass modifies the response. A subgroup difference that is not formally supported by an interaction test is a hypothesis, not a finding.

Finally, the authors flagged individual metabolic laboratory abnormalities that warrant further assessment. The abstract does not provide enough detail to characterize these, and they were not presented as a primary outcome. They are a reason for future trials to measure metabolic markers prospectively rather than as a secondary observation.

What this means for you

The honest summary is that this trial does not support using this pumpkin-seed peptide extract for weight or body composition change in overweight adults. The overall result was null, and the subgroup signal is too fragile to act on.

Several points are worth keeping in mind:

Product identity matters. This study tested one specific standardized preparation with a defined peptide profile. Other pumpkin-seed products may differ substantially in composition, and this evidence does not transfer to them automatically.

Small subgroups mislead. Thirteen participants is too few to draw reliable conclusions about who responds. Post hoc subgroup findings are a common source of false positives in nutrition research.

Established approaches have stronger evidence. For body composition, the best-supported levers remain sustained caloric balance and resistance training. Habits like Resistance training, Protein at every meal, and Daily steps target have far more supporting evidence than any single supplement from a trial of this size.

If you are considering a supplement for body composition, the question to ask is whether the product's specific formulation has been tested in an adequately powered, prospectively designed trial. This study does not yet meet that bar for this extract.

Study details

Item	Detail
Study type	Randomized, double-blind, placebo-controlled trial
Population	50 overweight adults (48 evaluable at Week 12)
Intervention	Standardized pumpkin-seed-derived preparation (IRK-19), 600 mg/day
Comparator	Placebo
Duration	12 weeks
Primary outcomes	Body weight, BMI, adiposity-related outcomes (DXA)
Overall result	No statistically significant between-group differences
Subgroup result	Post hoc, baseline fat mass at or above 28.4 kg (n = 13); not adjusted for multiple comparisons; interaction tests not significant
Journal	International Journal of Molecular Sciences
Evidence tier	C

Sources

1. Randomized clinical trial of a standardized pumpkin-seed-derived peptide extract: body composition outcomes and exploratory analysis by baseline adiposity in overweight adults. *International Journal of Molecular Sciences*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42884056/

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.